PTD-DBM Peptide Supplier China: 1mg COA Guide

Define both functional segments and their junction

Write the complete amino-acid sequence, identify the PTD and DBM boundaries, specify their order and junction, and state termini, modifications, counterion form, target purity, 1mg content, quantity and RUO status. Record expanded and abbreviated names as aliases to one controlled construct. Require the supplier's SKU to map to the same sequence on the quotation, specification, COA, analytical sample, label and packing list. A PTD-only peptide, DBM-only peptide or altered fusion order is not PTD-DBM equivalence.

Resolve sequence and modification variants before price review

Ask the supplier to provide its complete sequence notation and expected molecular information. Compare every residue, domain boundary, linker or junction, terminal group and modification with the buyer-approved construct. Record salt or counterion separately. A CAS reference or general Wnt-pathway description cannot resolve sequence ambiguity. Treat truncations, added residues, alternative PTDs or terminal changes as different materials requiring explicit scientific assessment and a new quotation, not as acceptable manufacturing variations.

Use HPLC and MS as complementary evidence

Require batch-linked HPLC and mass-spectrometry files. Check expected and observed molecular information, sample identifier, complete chromatogram, integration, method reference, dates, report number and authorization. Ask how the sample connects to bulk material and finished 1mg units. HPLC purity cannot alone establish the full fusion sequence or content, while a matching mass cannot prove residue order, positional isomers or purity. Preserve original data and investigate unexpected peaks, mass differences, untraceable third-party reports or revised files.

Verify the 1mg quantitative claim

Ask which suitable quantitative method or controlled filling record supports 1mg and what tolerance applies. Confirm whether the label means net PTD-DBM peptide or total lyophilized mass including counterions, water or excipients. Keep complete-construct identity, chromatographic purity and quantitative content as independent acceptance criteria. Reconcile issued, filled, rejected and retained quantities where applicable. Compare suppliers using total documented target peptide and equivalent analytical scope rather than vial count or headline purity.

Apply enhanced sequence and supplier controls

Map the legal seller, synthesis site, analytical laboratory, filling site, release authority, inventory owner and shipper. Confirm who owns the master sequence and original analytical records. Approve labels showing PTD-DBM, 1mg, lot and RUO wording. Require batch COA, HPLC and MS attachments, SDS, specification, storage statement, invoice and packing list to agree. For an evaluation lot, consider independent identity and content testing under documented sampling and custody before recurring wholesale approval.

Build one comparable wholesale RFQ matrix

Send every candidate the same fields: controlled identity, strength, vial count, total material, target purity or composition, identity method, quantitative-content basis, offered lot, testing status, packaging, documents, MOQ, lead time and shipping term. Mark missing answers as exceptions instead of filling gaps with assumptions. Separate testing, setup, customization and transport costs from recurring unit price. A standardized matrix gives scientific, purchasing and quality reviewers one auditable record and prevents an incomplete offer from appearing cheaper simply because it describes less work.

Apply a batch-focused quality-control review

Define every required attribute, acceptance criterion, method and record before purchase. Use the quality-control framework to connect each supplier claim to evidence and its method scope. Check sample identifiers, dates, report numbers, units and lot relationships across the complete reports. Batch-specific evidence is more decision-useful than a representative certificate. Preserve original files, record revisions and investigate contradictions before approving shipment. Where risk warrants, arrange independent testing under a documented sampling and custody plan.

Create a documentation gate before dispatch

List the required batch COA, analytical attachments, SDS, specification, supported storage statement, label proof, invoice and packing list in the RFQ and purchase order. Reconcile product, strength, lot, quantity and revision across records with the documentation guide. Require replacement documents when the offered lot changes. The importer remains responsible for current destination requirements. Research-use wording improves clarity but cannot guarantee customs entry or replace destination-specific legal and broker review.

Verify supplier and batch ownership

Document the legal seller, manufacturing site, analytical laboratory, filling or packaging site, inventory owner, release authority and dispatch entity for the exact SKU. A trading or coordination company can work with qualified partners, but roles and accountability must be transparent. Ask who owns the batch record, authorizes release, handles deviations and provides corrective action. Require advance notification when a critical party changes. Business-registration evidence supports identity but does not replace technical qualification of the offered lot.

Plan logistics and receiving controls

Confirm dispatch location, carrier, shipping term, packaging configuration and realistic production, release and transit windows. Reject guarantees of customs clearance or misleading declarations. On receipt, document package condition, seals, product, strength, lot and quantity, then connect internal inventory to the supplier batch. Store according to the applicable approved specification and quarantine unexplained damage, label conflicts, quantity differences or excursions until a documented quality decision is completed.

Use actual performance for repeat-order approval

A controlled evaluation order should use the same specification and evidence expectations planned for wholesale scale. Assess document accuracy, packaging, delivery time, communication and corrective response. Update a supplier scorecard from observed performance rather than catalog breadth or claims. For every new lot, repeat the batch review and approve current documents before dispatch. Require notification before changes to material specification, manufacturing, testing, filling, labels, packaging or other buyer-approved conditions.

Related products and same-category guides

• PTD-DBM 1mg
• PNC-27 Supplier Guide
• Custom Peptide Synthesis RFQ Checklist

Frequently asked questions